Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Anti-Müllerian hormone receptor type II (AMHR2) is a transmembrane serine/threonine kinase receptor that specifically binds anti-Müllerian hormone (AMH). AMHR2 is essential for mediating the biological effects of AMH, particularly in reproductive development and function. Upon binding AMH, AMHR2 activates downstream signaling pathways involving ALK-type I kinases and SMAD proteins, ultimately regulating gene expression. Loss-of-function mutations in AMHR2 are associated with persistent Müllerian duct syndrome.
Serine/threonine kinase receptor activation; SMAD pathway activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Anti-Müllerian Hormone Receptor Type II (None).